Toronto/Vancouver based Zucara Therapeutics secured US $21M Series A funding from Perceptive Xontogeny Venture Fund. Chris Garabedian and Fred Callori joined Zucara board.
Ampersand Capital Partners owned Nexelis to acquire ImmunXperts from Thibault Jonckheere, Sofie Pattij, Sambrinvest.
Fonds de solidarité FTQ committed €5M to Theodorus IV, a Université Libre de Bruxelles spinoff seed fund. Theodorus to open Montreal office led by Théo Risopoulos.
Trillium Therapeutics appointed New Enterprise Associates (NEA)’s Paul Walker and Dr. Ali Behbahani as Director and Board observer following US $116.95M offering
BenchSci secured US $22M Series B led by F-Prime Capital with participation from Northleaf Capital Partners, Gradient Ventures, Inovia Capital, Golden Ventures, and Real Ventures
Versant Ventures, New Enterprise Associates, RA Capital Management, Boxer Capital, LLC backed Black Diamond Therapeutics closed US $201M IPO on NASDAQ
FACIT seed stage Compass Rose Fund announced equity investments in Xpan Inc. and Nanology Labs.
Zymeworks, Trillium Therapeutics, Xenon Pharmaceuticals, Aptose Biosciences, Aurinia Pharmaceuticals, Sierra Oncology raising over US $800M or CND $1B in public financings
PhotoDynamic completed $2.3M round of financing with American Association of Orthodontists (AAO), Island Capital Partners (ICP), Natural Products Canada (NPC) and others
Nicoya Lifesciences secured $10M Series A from Whitecap Venture Partners, Garage Capital, MaRS IAF, Laurier Startup Fund, University of Waterloo Student Venture Fund, and others.
Fusion Pharmaceuticals Inc. secured up $20M Series B add-on funding from Canada Pension Plan Investment Board (CPPIB)
Aspect Biosystems secured US $20M in Series A funding from Radical Ventures, Pangaea Ventures, Pallasite Ventures, Rhino Ventures. Radical Ventures’ Salim Teja will join Aspect board
LQT Therapeutics, newly formed Long QT Syndrome therapeutics company, secured up to CDN $1.8M seed funding from Fonds de solidarité FTQ to continue to advance pre-clinical development of a series of novel compounds
Deep Genomics raised US $40M in Series B funding from Future Ventures, Amplitude Ventures, Khosla Ventures, Magnetic Ventures and True Ventures
General Atlantic backed Rubicon Research Private Limited acquired Impopharma Canada Limited
Synaptive Medical secured US $25M new preferred equity financing led by Linamar and Audible Capital with participation of a mix of both existing and new investors
Icentia closed a new round of financing with CIC Capital Ventures, Investissement Québec and private investors
